加载中
NASDAQHealthcareMedical - Care Facilities
最新数据
US$0.3799
+US$0.0049 · +1.31%
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
常规交易时段
US$0.3799
+US$0.0049 · +1.31%
盘中时间采用ET。市场数据可能有所延迟。
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
日内区间
当前US$0.3799
52周区间
当前US$0.3799
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
82
深度低估
情绪
58
多空交织
风险
79
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
日内区间
当前US$0.3799
52周区间
当前US$0.3799
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 204.51万 USD | 175.23万 USD | 142.43万 USD | 1105.91万 USD | 962.23万 USD |
| 销货成本 | 144.06万 USD | 139.2万 USD | 131.52万 USD | 593.74万 USD | 492.74万 USD |
| 毛利 | 60.45万 USD | 36.03万 USD | 10.91万 USD | 512.17万 USD | 469.5万 USD |
| 研究与开发 | 59.26万 USD | 126.18万 USD | 140.92万 USD | 12万 USD | 19.34万 USD |
| 销售、一般及管理费用 | 334.28万 USD | 475.96万 USD | 506.15万 USD | 332.28万 USD | 255.95万 USD |
| 营业费用 | 393.54万 USD | 602.14万 USD | 647.06万 USD | 344.29万 USD | 275.29万 USD |
| 利息收入 | 2.14万 USD | 7.95万 USD | 20.92万 USD | 6.84万 USD | 2994 USD |
| 利息支出 | 15.62万 USD | 1.26万 USD | 2.79万 USD | 1.57万 USD | 1.29万 USD |
| 折旧和摊销 | 7.8万 USD | 13.58万 USD | 16.73万 USD | 28.87万 USD | 12.37万 USD |
| 营业利润 | −333.09万 USD | −566.11万 USD | −636.15万 USD | 167.89万 USD | 194.21万 USD |
| 净利润 | −373.88万 USD | −555.17万 USD | −639.13万 USD | 218.69万 USD | 207.18万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
